BEIJING--(BUSINESS WIRE)--Jul 9, 2025--
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a global licensing agreement with BeOne Medicines Ltd., a global oncology company, for multiple fully human antibodies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250709204455/en/
Prior to this licensing agreement, BeOne Medicines had obtained a license to use Biocytogen’s RenMice ® fully human antibody platform. Building on this established collaboration, the new agreement expands the partnership into antibody license, further strengthening the strategic relationship between the two companies.
Dr. Yuelei Shen, President and CEO of Biocytogen, said, “BeOne Medicines is a global leader in drug development, and we are thrilled to enter into this strategic collaboration. The antibodies licensed under this agreement were discovered using our proprietary RenMice ® fully human antibody platform, highlighting our ability to empower partners in driving innovative drug discovery. We look forward to seeing these promising molecules progress rapidly into the clinic and ultimately bring transformative treatment options to patients worldwide.”
Under the terms of the agreement, Biocytogen will receive an upfront payment from BeOne Medicines. In addition, Biocytogen is eligible to receive development and regulatory milestone payments, commercial milestone payments, and tiered royalties based on future net sales of licensed products.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice ® (RenMab ™ / RenLite ® / RenNano ® / RenTCR-mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2024, approximately 200 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice ® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.
Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development
HANOI, Vietnam--(BUSINESS WIRE)--Jan 13, 2026--
FPT, through its global IT services subsidiary FPT Software, has achieved ISO/IEC 42001:2023, the first global standard for Artificial Intelligence (AI) Management Systems. With this milestone, FPT became the first company in Vietnam and the second in Southeast Asia to earn this recognition, underscoring its commitment to responsible AI development and deployment with consideration for fairness and impartiality, privacy and security, safety, quality and robustness, governance, transparency and explainability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112494011/en/
The certification was issued by the world’s leading testing, inspection and certification company SGS and qualified by ANAB (ANSI National Accreditation Board) - a leading U.S. accreditation body with global recognition. ISO/IEC 42001 specifies requirements for establishing, implementing, maintaining, and continually improving AI management systems, allowing organizations to effectively manage risks and opportunities associated with AI, balancing innovation with compliance.
Achieving ISO/IEC 42001:2023 reflects FPT’s capability in AI governance, encompassing ethics, risk management, transparency, compliance, and ensuring alignment with both business goals and societal values. It also strengthens FPT’s position as a trusted technology partner for global organizations, especially those in highly regulated industries such as banking and financial services, automotive, healthcare, energy, and the public sector. The milestone further solidifies FPT’s position as an AI-first company, strengthening its foundation for scaling AI responsibly while helping clients navigate evolving regulatory, ethical, and operational challenges associated with AI adoption.
“As an AI-first company, we pledge to prioritize safety, ethics and accountability at every stage of our AI lifecycle. By continuously governing AI development and implementation processes, we provide our clients and partners with the assurance that our solutions are built with responsibility, transparency and adhere to international excellence,” said Dao Duy Cuong, FPT Software EVP and Chief Digital & Technology Officer, FPT Corporation.
FPT actively promotes responsible AI development as a founding member of the AI Alliance led by IBM and Meta, and the Vietnam Ethical AI Committee. The company is committed to embedding rigorous AI governance across its global operations and solution portfolio, including its flagship AI platform FleziPT, which boosts productivity by 30%, accelerates development by 60% and reduces 50% in rework. The company also maintains co-creation partnerships with global leaders like AWS, Microsoft, SAP, and NVIDIA to deliver tailored solutions for industry-specific challenges. Supporting these efforts is a workforce of over 25,000 AI-augmented, globally certified engineers, and world-class infrastructure including cutting-edge AI Factories in Vietnam and Japan, which have been ranked among the world’s Top 40 fastest supercomputers. Expanding its AI footprint, FPT is developing a new Research Center in Gia Lai Province, Vietnam, which is expected to become a critical component of its global AI development network, supporting high-quality talent cultivation for both the local community and the nation.
About FPT
FPT Corporation (FPT) is a globally leading technology and IT services provider headquartered in Vietnam, operating in three core sectors: Technology, Telecommunications, and Education. Over more than three decades, FPT has consistently delivered impactful solutions to millions of individuals and tens of thousands of organizations worldwide. As an AI-first company, FPT is committed to elevating Vietnam’s position on the global tech map and delivering world-class AI-enabled solutions for global enterprises. FPT focuses on three critical transformations: Digital Transformation, Intelligence Transformation, and Green Transformation. In 2024, FPT reported a total revenue of USD 2.47 billion and a workforce of over 54,000 employees across its core businesses. For more information about FPT's global IT services, please visit https://fptsoftware.com.
FPT received ISO/IEC 42001:2023 certification during the certification award ceremony in Hanoi, Vietnam
